ALKBH5 acts as a modification switch of lncRNA SOX2OT and participates in the lncRNA-mediated competitive endogenous RNA model to enhance the molecular stability and exploit the function of SOX2OT, thus affecting progression and drug resistance in glioma [22]. Here, SOX2-OT is linked to central nervous system cancer.